Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group

Simple item page
dc.contributor.authorTanriverdi O.
dc.contributor.authorCokmert S.
dc.contributor.authorOktay E.
dc.contributor.authorPilanci K.N.
dc.contributor.authorMenekse S.
dc.contributor.authorKocar M.
dc.contributor.authorSen C.A.
dc.contributor.authorAvci N.
dc.contributor.authorAkman T.
dc.contributor.authorOrdu C.
dc.contributor.authorGoksel G.
dc.contributor.authorMeydan N.
dc.date.accessioned2024-07-22T08:15:48Z
dc.date.available2024-07-22T08:15:48Z
dc.date.issued2014
dc.description.abstractNon-small cell lung cancer (NSCLC) is one of the most common cancers. Most of the patients are inoperable at the time of diagnosis, and the prognosis is poor. Many prognostic factors have been identified in prior studies. However, it is not clear which factor is more useful. In this study, we investigated whether uric acid, the last breakdown product of purine metabolism in humans, has a prognostic significance in advanced NSCLC. A total of 384 NSCLC patients at stage IIIB/IV and who did not meet exclusion criteria were included in this retrospective cross-sectional study. The patients’ serum uric acid levels before first-line chemotherapy and demographic (age, gender, smoking), clinical (performance status, weight loss, disease stage, first-line treatment regimen), laboratory (hemoglobin, lactate dehydrogenase), and histologic (histologic type, tumor grade) characteristics were recorded. First, a cut-off value was determined for serum uric acid level. Then, the patients were stratified into four groups (quartiles) based on their serum uric acid levels. Descriptive statistics, univariate and multivariate analyses, and survival analyses were used. Majority of the patients were males, smokers and metastatic at time of diagnosis and had history of weight loss and adenocarcinoma upon pathological examination. The serum uric acid levels of all patients were determined as 4.9 ± 2.9 (range 1.9–11.3). The patients were stratified according to quartiles of serum uric acid concentration with cutoff values defined as <3.08 mg/dL (lowest quartile, Group 1), 3.09–5.91 mg/dL (Group 2), 5.92–7.48 mg/dL (Group 3), and >7.49 mg/dL (highest quartile, Group 4). Among the patients who had serum uric acid levels over 7.49, it was observed that those who also had squamous cell carcinoma had a greater rate of brain metastasis, a shorter time lapse until brain metastasis, and lower overall survival rate. It can be assumed that NSCLC patients who had histologically shown squamous cell carcinoma display brain metastasis and poor prognosis. It can be recommended to repeat this study with larger patient series including immunohistochemical, molecular, and wider laboratory investigations. © 2014, Springer Science+Business Media New York.
dc.identifier.DOI-ID10.1007/s12032-014-0217-z
dc.identifier.issn13570560
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16766
dc.language.isoEnglish
dc.publisherHumana Press Inc.
dc.subjectAged
dc.subjectAntineoplastic Agents
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectCross-Sectional Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectL-Lactate Dehydrogenase
dc.subjectLeukocyte Count
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMedical Oncology
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectPlatelet Count
dc.subjectPrognosis
dc.subjectRisk Factors
dc.subjectSurvival Rate
dc.subjectTurkey
dc.subjectUric Acid
dc.subjectantineoplastic agent
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectdocetaxel
dc.subjectgemcitabine
dc.subjecthemoglobin
dc.subjectlactate dehydrogenase
dc.subjectpaclitaxel
dc.subjecturic acid
dc.subjectantineoplastic agent
dc.subjectlactate dehydrogenase
dc.subjecturic acid
dc.subjectadenosquamous carcinoma
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectbrain metastasis
dc.subjectcancer combination chemotherapy
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectcross-sectional study
dc.subjectdemography
dc.subjectfemale
dc.subjecthemoglobin blood level
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectlactate dehydrogenase blood level
dc.subjectlarge cell lung carcinoma
dc.subjectleukocyte count
dc.subjectlung adenocarcinoma
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnon small cell lung cancer
dc.subjectoverall survival
dc.subjectretrospective study
dc.subjectsmoking
dc.subjectsquamous cell lung carcinoma
dc.subjectthrombocyte count
dc.subjecturic acid blood level
dc.subjectweight reduction
dc.subjectblood
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectoncology
dc.subjectorganization and management
dc.subjectpathology
dc.subjectprognosis
dc.subjectrisk factor
dc.subjectsecondary
dc.subjectsurvival rate
dc.subjectTurkey
dc.titlePrognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group
dc.typeArticle

Files

Collections

Scopus Koleksiyonu